Reviva Pharmaceuticals Holdings, Inc.

NasdaqCM:RVPH Stock Report

Market Cap: US$62.9m

Reviva Pharmaceuticals Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Laxminarayan Bhat

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage16.3%
CEO tenure18.7yrs
CEO ownership7.4%
Management average tenureno data
Board average tenure4.1yrs

Recent management updates

Recent updates

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Dec 11

Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

Aug 24
Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely

We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Dec 28
We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals drops 9% on $8.5M private placement

Sep 06

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Aug 24
We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

Reviva Pharmaceuticals Q2 GAAP loss per share widens

Aug 15

Reviva reports positive brilaroxazine results in Aacute Schizophrenia

Apr 26

CEO Compensation Analysis

How has Laxminarayan Bhat's remuneration changed compared to Reviva Pharmaceuticals Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$33m

Jun 30 2024n/an/a

-US$36m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$3mUS$450k

-US$39m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$34m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$560kUS$400k

-US$28m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$600kUS$400k

-US$9m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$4m

Dec 31 2020US$248kUS$248k

-US$4m

Sep 30 2020n/an/a

-US$2m

Jun 30 2020n/an/a

-US$2m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$240kUS$240k

-US$847k

Dec 31 2018US$240kUS$240k

-US$2m

Compensation vs Market: Laxminarayan's total compensation ($USD2.76M) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Laxminarayan's compensation has increased whilst the company is unprofitable.

CEO

Laxminarayan Bhat (59 yo)

18.7yrs

Tenure

US$2,764,747

Compensation

Dr. Laxminarayan Bhat, Ph D., serves as the Founder of Reviva Pharmaceuticals Holdings, Inc. since 2006 and has been its Director since 2006 and serves as its President and Chief Executive Officer since Ma...

Board Members

NamePositionTenureCompensationOwnership
Laxminarayan Bhat
Founder19yrsUS$2.76m7.43%
$ 4.7m
Parag Saxena
Independent Chairman of the Board4.1yrsUS$107.01k2.61%
$ 1.6m
John Kane
Member of Advisory Boardno datano datano data
Daphne Karydas
Member of Advisory Boardno datano datano data
Les Funtleyder
Independent Director4.1yrsUS$88.01k0%
$ 0
Richard Margolin
Independent Director4.1yrsUS$81.76k0%
$ 0
Roham Zamanian
Member of Advisory Boardno datano datano data
Leslie Citrome
Member of Advisory Boardno datano datano data
Purav Patel
Independent Director7.7yrsUS$90.51k0.27%
$ 172.5k
Martin Kolb
Member of Advisory Boardno datano datano data

4.1yrs

Average Tenure

56.5yo

Average Age

Experienced Board: RVPH's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/13 08:17
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Reviva Pharmaceuticals Holdings, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Bruce JacksonBenchmark Company
Jason KolbertD. Boral Capital LLC.